Structure via PubChem · Public domain (PubChem)
YCT529
Sign in to saveAlso known as 4-[5-[2,2-dimethyl-4-(4-methylphenyl)chromen-6-yl]-1H-pyrrol-2-yl]benzoic acid
YCT529 is an experimental non-hormonal male contraceptive developed by YourChoice Therapeutics. It functions as a selective antagonist of the retinoic acid receptor alpha (RAR-α), a nuclear receptor involved in vitamin A signaling. By inhibiting RAR-α, YCT529 disrupts spermatogenesis, leading to temporary infertility. YCT529 targets RAR-α, which plays a crucial role in the vitamin A signaling pathway essential for sperm production. By selectively inhibiting RAR-α, the drug impedes the development and maturation of sperm cells without affecting other physiological processes governed by vitamin
Chemical data
- Formula
- C29H25NO3
- Molecular weight
- 435.5 g/mol
- IUPAC name
- 4-[5-[2,2-dimethyl-4-(4-methylphenyl)chromen-6-yl]-1H-pyrrol-2-yl]benzoic acid
- SMILES
- CC1=CC=C(C=C1)C2=CC(OC3=C2C=C(C=C3)C4=CC=C(N4)C5=CC=C(C=C5)C(=O)O)(C)C
- InChIKey
- QLXSCDXZOYRDAX-UHFFFAOYSA-N
- XLogP
- 6
- Polar surface area
- 62.3 Ų
- H-bond donors
- 2
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 435.18344365999997
Show 3 more facts
- canonical SMILES
- CC1=CC=C(C=C1)C2=CC(OC3=C2C=C(C=C3)C4=CC=C(N4)C5=CC=C(C=C5)C(=O)O)(C)C
- Commons category
- YCT529
- chemical formula
- C₂₉H₂₅NO₃
Sources (1)
via Wikidata · CC0
~2 min read
Encyclopedic overview
6 sectionsContents
- Preclinical studies
- Clinical trials
- Development and funding
- See also
- References
- Further reading
YCT529 is an experimental non-hormonal male contraceptive developed by YourChoice Therapeutics. It functions as a selective antagonist of the retinoic acid receptor alpha (RAR-α), a nuclear receptor involved in vitamin A signaling. By inhibiting RAR-α, YCT529 disrupts spermatogenesis, leading to temporary infertility. YCT529 targets RAR-α, which plays a crucial role in the vitamin A signaling pathway essential for sperm production. By selectively inhibiting RAR-α, the drug impedes the development and maturation of sperm cells without affecting other physiological processes governed by vitamin A.
== Preclinical studies == In preclinical trials involving male mice, YCT529 demonstrated a 99% efficacy rate in preventing pregnancy. The contraceptive effect was fully reversible, with fertility restored within four to six weeks after discontinuation. No significant side effects were observed during these studies. Similar outcomes were reported in studies with non-human primates, where sperm counts decreased significantly after two weeks of dosing, and normal fertility resumed post-treatment.
Excerpted from Wikipedia’s “YCT529” article, available under the CC BY-SA 4.0 licence.